Reconciliation with Solitude
Release time:
2022-02-21
person, you must meet at least one such person: he understands your sleepless night, understands your unspeakable concealment, he can listen to you tell your story, tell the scenery you have seen, the people and things you have met, the wind and rain you have experienced. In his life, to meet such a person, or a close friend, or a partner, is enough to make people feel happy.
used to believe for a long time that "people's life loneliness is the norm " . when you see the students around you in groups, when your family doesn't understand you, you always use this sentence to convince yourself that you won't feel too sad. After a long time, I found that this sentence seems to be more and more unable to convince myself. I am full of yearning for places that are lively and full of human fireworks. Even if I sometimes know that I am not suitable or can't fit in, I always can't restrain the yearning in my heart and want to get closer and closer. There have been many friends in the journey of life, and the company time is always limited, as short as a few days and months, as long as a few years. Seeing your ups and downs, seeing your ambition, but they can only accompany you through the journey of life.
people always have to learn to grow up in loneliness, more often in mind and spirit. This loneliness is difficult to express in words. It may be revealed in his eyes and his back. Maybe when he is in a lot of hilarity, he is still alone. Maybe he has many friends, there are many people around him every day, and everyone doesn't think he will be lonely. But the fact is that he seeks company again and again, and finally fails again and again, thus convincing himself to accept this loneliness. Even if the side is full of laughter, still surrounded by deep loneliness, want to change, but can not change.
Later, when one or several people appeared in my life, it made me feel as if the normal state of life was more than just loneliness. When I am happy, I can share my happiness. Small happiness seems to have become double happiness. When I am sad and wronged, I have a good listener, as if after talking, the pain can be halved. When I hesitate, it seems that I am not the only one who can have business and quantity to find the better choice together ... Therefore, my life seems to have added different colors in addition to the original background color. A person's sense of loneliness has gradually faded, and the warmth of many people has gradually become the main color, and it also makes people feel the happiness of companionship. It is probably due to the general environment that social interaction is now faster and more convenient. In the past, the companionship around us has gradually become the companionship across the mobile phone screen, and the meals cooked by ourselves have become the takeout ordered by ourselves. In my opinion, such changes are always lack of human touch and warmth. Therefore, I always want to cherish this one or these people well, so that they can accompany me longer, maybe they can accompany me to grow up and grow old.
The word company is always full of warmth and love, and it is more worthy of our cherishing. In this way, it seems that reconciliation with loneliness is not impossible.
(Wang Junxiao)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31